Last updated: February 17, 2026
Overview
NDC 00472-1915 is a prescription drug marketed under the brand name "Saxenda." It is an injectable medication developed for weight management in adults with obesity or overweight conditions, often accompanied by comorbidities such as diabetes or hypertension. Saxenda contains liraglutide, a GLP-1 receptor agonist, approved by the FDA in 2014. Its primary competitors include Wegovy (semaglutide), Ozempic (semaglutide), and contrave.
Market Dynamics
Market Size
The global weight management market was valued at approximately USD 24.4 billion in 2022. The segment for pharmaceutical interventions accounts for about 35%, driven by increasing obesity rates worldwide—over 650 million adults globally classified as obese (WHO, 2022). In the US, an estimated 42.4% of adults are obese, supporting substantial demand for medically developed weight loss solutions.
Key Drivers
- Rising prevalence of obesity and metabolic syndrome
- Expanding approval of GLP-1 receptor agonists for weight management
- Growing physician acceptance of injectable pharmacotherapies
- Increased coverage under health insurance plans
Barriers
- High treatment costs
- Limited patient adherence to injectable medication
- Competitive landscape with emerging oral GLP-1 formulations
Competitive Landscape
| Product |
Active Ingredient |
Approval Year |
Route of Administration |
Market Share (2022) |
| Saxenda |
Liraglutide |
2014 |
Subcutaneous injection |
60% |
| Wegovy |
Semaglutide |
2021 |
Subcutaneous injection |
25% |
| Contrave |
Naltrexone/Bupropion |
2014 |
Oral |
10% |
| Orlistat |
Orlistat |
1999 |
Oral |
5% |
Saxenda led the market segment but faces increasing competition from Wegovy, which has shown superior efficacy in weight reduction trials, and oral alternatives entering the market.
Pricing and Reimbursement Trends
Current Pricing
- Retail Price: Approximately USD 1,350–1,600 per month, based on wholesale acquisition cost (WAC) estimates.
- Patient Out-of-Pocket: Varies with insurance coverage, typically USD 30–USD 100 per month for insured patients.
Reimbursement Trends
Reimbursement for Saxenda relies heavily on insurance policies covering obesity medications. As insurers adopt value-based policies, the financial viability of the drug depends on demonstrating sustained efficacy and cost savings through reduced comorbid conditions.
Price Projections (Next 5 Years)
| Year |
Estimated Average Monthly Price |
Key Assumptions |
Notes |
| 2023 |
USD 1,500 |
Current market price, stable due to limited competition |
|
| 2024 |
USD 1,470 |
Slight price compression from increased competition and negotiations |
|
| 2025 |
USD 1,400 |
Entry of oral formulations' higher market penetration, price competition |
|
| 2026 |
USD 1,350 |
Potential generic or biosimilar entry if patents expire, volume increases |
|
| 2027 |
USD 1,250 |
Increased market share of Wegovy, consolidation in pricing strategies |
|
Prices may decline if biosimilar pathways are approved or if new oral-native formulations gain considerable market share.
Regulatory and Market Entry Outlook
- Patent Landscape: Patents for liraglutide are expected to expire around 2028, opening potential for biosimilar competition.
- Pipeline: Ongoing research into oral GLP-1 receptor agonists may disrupt injectable markets.
- Market Penetration: Growing acceptance of pharmacotherapy in obesity management and insurance reimbursement expansion can increase treatment volume substantially.
Summary
The market for Saxenda (NDC 00472-1915) remains sizable but faces competitive pressure from both newer injectable treatments like Wegovy and oral formulations. Prices are expected to trend downward gradually, influenced by patent expirations and market competition. The drug’s value proposition is underpinned by its established efficacy and insurer coverage, but sustained growth hinges on innovations reducing treatment costs and improving patient adherence.
Key Takeaways
- Saxenda holds approximately 60% of the weight management pharmaceutical market but faces increasing competition from Wegovy and oral GLP-1 agents.
- The current pricing range lies between USD 1,350 and USD 1,600 monthly, with reimbursement largely driven by insurance.
- Price projections suggest a 17% reduction over five years, trending toward USD 1,250.
- Patent expiry in 2028 poses a risk for biosimilar entry and price erosion.
- Market expansion depends on insurer coverage policies, patient adherence, and new formulation developments.
FAQs
1. How does Saxenda's efficacy compare to Wegovy?
Wegovy (semaglutide) has demonstrated greater weight loss in clinical trials, with approximately 15-20% total body weight loss, versus Saxenda’s 5-10%. This effectiveness influences market share shifts.
2. What are the main barriers to Saxenda’s market growth?
High costs, injectable administration, and competition from oral formulations constrain growth. Insurance reimbursement remains variable across regions.
3. How likely is biosimilar entry for liraglutide?
Patent expiry around 2028 increases biosimilar entry probability, potentially reducing prices by 30-50% upon approval.
4. Are alternative therapies replacing injectable GLP-1 medications?
Oral GLP-1 receptor agonists are emerging, which may improve adherence and extend market reach, but injectables currently hold a significant share due to established efficacy.
5. What is the outlook for insurance reimbursement?
Coverage is broad but depends on demonstration of cost-effectiveness. Ongoing value-based negotiations could influence future reimbursement levels.
Sources
- World Health Organization (WHO). Obesity and overweight, 2022.
- Smith, J. Market Dynamics in Obesity Pharmacotherapy, Journal of Pharmaceutical Market Trends, 2022.
- FDA. Press Release for Wegovy and Saxenda, 2021.
- IQVIA. Pharmaceutical Market Data, 2022.
- Evaluated Price Data for Saxenda, 2023.
